GENE: AI 评分 43/100 — AI 分析 (4月 2026)

Genetic Technologies Limited is a molecular diagnostics company focused on predictive testing and assessment tools for women's health. Their lead product, BREVAGenplus, assesses non-hereditary breast cancer risk, with expansion into other disease risk assessments.

Key Facts: AI Score: 43/100 Sector: Healthcare

公司概况

概要：

Genetic Technologies Limited is a molecular diagnostics company providing predictive testing for women's health, primarily through its BREVAGenplus breast cancer risk assessment. Operating in the medical diagnostics sector, the company focuses on expanding its GeneType platform to include various disease risk assessments in both Australia and the United States.

GENE是做什么的？

Genetic Technologies Limited, established in 1987 and headquartered in Fitzroy, Australia, is a molecular diagnostics company specializing in predictive testing and assessment tools. The company focuses on helping physicians manage women's health through early risk detection. Its flagship product, BREVAGenplus, is a clinically validated risk assessment test designed to predict non-hereditary breast cancer risk. This test is marketed to healthcare professionals, including those in breast health and imaging centers, obstetricians/gynecologists, and breast cancer risk assessment specialists. Beyond BREVAGenplus, Genetic Technologies offers a range of cancer risk assessment tests under the GeneType brand, covering colorectal and breast cancer. The company is also developing risk assessment tests for other diseases, including cardiovascular disease, type 2 diabetes, prostate cancer, and melanoma, aiming to broaden its diagnostic offerings. Additionally, Genetic Technologies provides genetic testing services for medical, animal, forensic, and plant applications, diversifying its revenue streams. Genetic Technologies has established research and collaboration agreements with several institutions, including the University of Melbourne, Translational Genomics Research Institute, Memorial Sloan Kettering New York Cambridge University, the Ohio State University, and Shivom, to support its research and development efforts and expand its scientific knowledge base.

GENE的投资论点是什么？

Genetic Technologies Limited presents a speculative investment thesis centered on its BREVAGenplus and GeneType platforms for disease risk assessment. The company's potential lies in expanding its product offerings and market reach within the growing predictive diagnostics market. Key value drivers include increasing adoption of BREVAGenplus by healthcare providers and successful development and commercialization of new GeneType tests for diseases like cardiovascular disease and type 2 diabetes. The company's gross margin of 50.9% indicates pricing power. However, its negative P/E ratio of -0.45 and profit margin of -156.8% highlight significant profitability challenges. Ongoing: The company's ability to achieve profitability and manage its cash burn will be critical for long-term success.

GENE在哪个行业运营？

Genetic Technologies Limited operates within the medical diagnostics and research industry, a sector characterized by rapid innovation and increasing demand for personalized medicine. The market for genetic testing is projected to grow, driven by advancements in technology and a growing awareness of the benefits of early disease detection. The company faces competition from established players like Exact Sciences (CYT) and smaller, specialized diagnostics firms. Success in this industry requires continuous innovation, strong intellectual property protection, and effective marketing to healthcare providers.

Medical - Diagnostics & Research

Healthcare

GENE有哪些增长机遇？

Expansion of GeneType product line: Genetic Technologies has the opportunity to expand its GeneType platform to include risk assessment tests for diseases such as cardiovascular disease, type 2 diabetes, prostate cancer, and melanoma. The market for these tests is substantial, with cardiovascular disease alone affecting millions of people worldwide. Successful development and commercialization of these tests could significantly increase the company's revenue and market share. Timeline: 2-3 years for initial test launches.
Increased adoption of BREVAGenplus: Genetic Technologies can increase the adoption of its BREVAGenplus breast cancer risk assessment test by expanding its marketing efforts and targeting healthcare professionals in breast health and imaging centers, obstetricians/gynecologists, and breast cancer risk assessment specialists. The market for breast cancer risk assessment is growing, driven by increasing awareness of the importance of early detection. Timeline: Ongoing.
Geographic expansion: Genetic Technologies currently operates in Australia and the United States. Expanding into other geographic markets, such as Europe and Asia, could significantly increase the company's revenue and market share. These markets have a growing demand for genetic testing and personalized medicine. Timeline: 3-5 years for significant expansion.
Strategic partnerships and collaborations: Genetic Technologies can leverage strategic partnerships and collaborations with research institutions, healthcare providers, and other companies to expand its product offerings, market reach, and scientific knowledge base. The company already has research agreements with several universities and research institutes. Timeline: Ongoing.
Development of personalized medicine solutions: Genetic Technologies can leverage its expertise in genetic testing to develop personalized medicine solutions that tailor treatment plans to individual patients based on their genetic profiles. The market for personalized medicine is growing rapidly, driven by advancements in genomics and proteomics. Timeline: 5+ years for significant impact.

Market capitalization of $0.11 billion, reflecting its small-cap status within the healthcare sector.
Gross margin of 50.9%, indicating a strong ability to control the cost of goods sold.
Negative P/E ratio of -0.45, suggesting the company is currently unprofitable.
Profit margin of -156.8%, highlighting significant challenges in achieving profitability.
Beta of 0.48, indicating lower volatility compared to the overall market.

GENE提供哪些产品和服务？

Develops and commercializes predictive testing and assessment tools.
Offers BREVAGenplus, a risk assessment test for non-hereditary breast cancer.
Markets GeneType for Colorectal Cancer and GeneType for Breast Cancer.
Develops risk assessment tests for cardiovascular disease, type 2 diabetes, prostate cancer, and melanoma.
Provides genetic testing services for medical, animal, forensic, and plant applications.
Collaborates with research institutions to expand its scientific knowledge base.

GENE如何赚钱？

Generates revenue through the sale of its BREVAGenplus and GeneType risk assessment tests.
Provides genetic testing services to various industries, including medical, animal, forensic, and plant.
Partners with healthcare providers and research institutions to expand its market reach and product offerings.

Healthcare professionals, including those in breast health and imaging centers.
Obstetricians/gynecologists.
Breast cancer risk assessment specialists, such as breast surgeons.
Individuals seeking genetic testing services.

Proprietary technology and intellectual property related to its BREVAGenplus and GeneType tests.
Established relationships with healthcare providers and research institutions.
Clinical validation of its BREVAGenplus test.
Expertise in genetic testing and personalized medicine.

什么因素可能推动GENE股价上涨？

Upcoming: Expansion of the GeneType test menu to include additional disease risk assessments, such as cardiovascular disease and type 2 diabetes. This could drive revenue growth and increase market share.
Ongoing: Increased adoption of BREVAGenplus by healthcare providers and patients. This will depend on the company's marketing efforts and the clinical validation of the test.
Ongoing: Strategic partnerships and collaborations with research institutions and healthcare providers. These partnerships could expand the company's product offerings and market reach.
Ongoing: Positive results from clinical trials and studies evaluating the effectiveness of its tests. This could increase confidence in the company's products and drive adoption.

GENE的主要风险是什么？

Potential: Competition from established diagnostics companies with greater resources and market share. This could limit the company's ability to grow its revenue and market share.
Potential: Changes in healthcare regulations and reimbursement policies. This could negatively impact the demand for the company's products and services.
Potential: Patent expiration and intellectual property challenges. This could allow competitors to copy the company's products and reduce its competitive advantage.
Ongoing: The company's negative profitability and high operating expenses. This could lead to financial difficulties and the need to raise additional capital.
Ongoing: Reliance on a small number of products for revenue. This makes the company vulnerable to changes in demand for those products.

GENE的核心优势是什么？

Clinically validated BREVAGenplus test.
Expanding GeneType product line.
Research and collaboration agreements with leading institutions.
Expertise in genetic testing and personalized medicine.

GENE的劣势是什么？

Negative profitability and high operating expenses.
Limited market share compared to larger competitors.
Dependence on a small number of products for revenue.
Small company size with 55 employees.

GENE有哪些机遇？

Expansion into new geographic markets.
Development of personalized medicine solutions.
Increased adoption of BREVAGenplus and GeneType tests.
Strategic partnerships and collaborations.

GENE面临哪些威胁？

Competition from established diagnostics companies.
Changes in healthcare regulations and reimbursement policies.
Patent expiration and intellectual property challenges.
Technological advancements that could render its products obsolete.

GENE的竞争对手是谁？

Augurex Life Sciences Corp — Focuses on autoimmune disease diagnostics. — (AUGX)
Exact Sciences Corp — Specializes in early cancer detection. — (CYT)
Genetron Holdings Ltd — Offers precision oncology solutions. — (GTH)
HilleVax Inc — Develops and commercializes novel vaccines. — (HLVX)
iCAD Inc — Provides cancer detection and therapy solutions. — (ICAD)

Key Metrics

MoonshotScore: 43/100

Company Profile

CEO: Kevin Camilleri
Headquarters: Fitzroy, AU
Employees: 55
Founded: 2005

AI Insight

AI analysis pending for GENE

ADR Level: 2
ADR Ratio: 1:1

常见问题

What does Genetic Technologies Limited do?

Genetic Technologies Limited is a molecular diagnostics company focused on predictive testing and assessment tools, primarily in women's health. Its main product is BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. The company also offers GeneType tests for colorectal and breast cancer, and it is developing tests for other diseases like cardiovascular disease and type 2 diabetes. Additionally, Genetic Technologies provides genetic testing services for medical, animal, forensic, and plant applications, serving a diverse range of customers.

What do analysts say about GENE stock?

As of March 16, 2026, a comprehensive analyst consensus for Genetic Technologies Limited (GENE) is pending. Key valuation metrics to consider include its market capitalization of $0.11 billion and its negative P/E ratio of -0.45, reflecting its current lack of profitability. Growth considerations revolve around the successful expansion of its GeneType product line and increased adoption of BREVAGenplus. Investors should monitor the company's progress in achieving profitability and managing its cash burn.

What are the main risks for GENE?

Genetic Technologies Limited faces several key risks. Competition from larger, more established diagnostics companies poses a significant threat. Changes in healthcare regulations and reimbursement policies could negatively impact demand for its products. Patent expiration and intellectual property challenges could erode its competitive advantage. The company's current negative profitability and reliance on a limited product portfolio also present financial and operational risks. Successfully mitigating these risks is crucial for the company's long-term success.

How does Genetic Technologies Limited generate revenue in the healthcare sector?

Genetic Technologies Limited primarily generates revenue through the sale of its predictive testing and assessment tools, particularly BREVAGenplus and the GeneType series of tests. These tests are marketed to healthcare professionals, including those in breast health and imaging centers, obstetricians/gynecologists, and breast cancer risk assessment specialists. Revenue is also derived from genetic testing services offered to medical clients. The company's ability to expand its test menu and increase adoption of its existing products will be critical for driving revenue growth in the healthcare sector.

How does Genetic Technologies Limited protect its intellectual property and maintain a competitive edge?

Genetic Technologies Limited relies on patents and proprietary technology to protect its intellectual property and maintain a competitive edge in the molecular diagnostics market. The company's BREVAGenplus test and GeneType platform are based on unique algorithms and methodologies. Ongoing research and development efforts are focused on developing new and improved tests, as well as expanding the company's patent portfolio. Strategic collaborations with research institutions also contribute to the company's intellectual property and competitive position.